KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $7.3 billion.

  • Gilead Sciences' Cash & Equivalents rose 4552.31% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year increase of 4552.31%. This contributed to the annual value of $10.0 billion for FY2024, which is 6419.06% up from last year.
  • Per Gilead Sciences' latest filing, its Cash & Equivalents stood at $7.3 billion for Q3 2025, which was up 4552.31% from $5.1 billion recorded in Q2 2025.
  • Gilead Sciences' Cash & Equivalents' 5-year high stood at $10.0 billion during Q4 2024, with a 5-year trough of $2.8 billion in Q2 2024.
  • Over the past 5 years, Gilead Sciences' median Cash & Equivalents value was $5.0 billion (recorded in 2024), while the average stood at $5.4 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 6614.93% in 2021, then soared by 8557.0% in 2025.
  • Quarter analysis of 5 years shows Gilead Sciences' Cash & Equivalents stood at $5.3 billion in 2021, then grew by 1.39% to $5.4 billion in 2022, then grew by 12.44% to $6.1 billion in 2023, then soared by 64.19% to $10.0 billion in 2024, then decreased by 26.63% to $7.3 billion in 2025.
  • Its Cash & Equivalents was $7.3 billion in Q3 2025, compared to $5.1 billion in Q2 2025 and $7.9 billion in Q1 2025.